Recently, it was reported that kinase inhibitors, such as sorafenib (Nexavarand) and pazopanib (Votrient) (Table 2), were linked to the inhibition of Hsp90 activity in HER2-positive breast cancer cells [63]. Here, ERBB2 is linked to breast carcinoma.